Clinical Trial

Applying the Pathways and Resources for Engagement and Participation Protocol Among People With Muscles Dystrophies

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 6, 2024 (before its estimated February 2025 completion). Its status may not reflect the trial's current state.
Summary
Taking part in community activities is essential for health and well-being. Yet, it is highly restricted for young people with Duchenne and Becker Muscular Dystrophies (DBMD), especially as they grow into adulthood. The Participation Pathways and Resources for Engagement and Participation (PREP) intervention is designed to help remove barriers in the environment. This study aims to see if the PREP intervention is useful and practical for youth and young adults with DBMD. The main question is: How useful is the PREP intervention for improving participation in community-based activities chosen by the participants? Participants will start the study at different times (4, 5, or 6 weeks) and work one-on-one with an occupational therapist on a leisure activity of their choice. They will have eight sessions over 12 to 18 weeks to work on this activity. They will use the Canadian Occupational Performance Measure (COPM) every week to track their performance and satisfaction with the chosen activity before, during, and after the intervention. The findings of this study can guide clinicians, families, and policymakers to select effective approaches that promote the participation of youth and young adults with DBMD in 'real world' activities they choose. It can also increase motivation and compliance and reduce the burden on the healthcare system, families, and people with DBMD themselves.
Trial Details
NCT Number NCT06540365
Lead Sponsor University of Haifa
Collaborators: McGill University
Conditions Duchenne Muscular Dystrophy, Becker Muscular Dystrophy
Enrollment 6 participants
Start Date 2024-08
Primary Completion 2025-02 (estimated)
Study Completion 2025-02 (estimated)
Updated on ClinicalTrials.gov 2024-08-06